White & Case advised GlaxoSmithKline plc, a science-led global healthcare company, in its global strategic alliance with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy that is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers.
The total potential deal value is up to €3.7 billion. Both companies will jointly conduct development and commercialization with all profits and costs from the collaboration being shared equally on a global basis.
The White & Case attorney who led this matter is partner Andres Liivak (Picture) in New York.
Involved fees earner: Andres Liivak – White & Case;
Law Firms: White & Case;
Clients: GlaxoSmithKline plc;